Exosome Diagnostics Completes $30 Million Series C Financing
in portfolio news
Exosome Diagnostics Inc., a leader in the liquid biopsy market, today announced the close of its $30 million Series C financing, led by insiders, Tiger Partners and Forbion Capital Partners. Blue Ridge Capital, NGN Capital, Arcus Ventures, b-to-v Partners, CD Ventures and others participated in the round, which was oversubscribed.
Exosome Diagnostics intends to use the funds to support the rapid commercial expansion of its ExoDx® Prostate(IntelliScore) and other diagnostic tests in the oncology market. The company will also continue to leverage its proprietary technologies for tests in other areas, such as neurodegenerative diseases, transplant rejection monitoring, and cardiology.